domingo, 25 de mayo de 2014

Buruli Ulcer Disease in Republic of the Congo - Volume 20, Number 6—June 2014 - Emerging Infectious Disease journal - CDC

Buruli Ulcer Disease in Republic of the Congo - Volume 20, Number 6—June 2014 - Emerging Infectious Disease journal - CDC

link to Volume 20, Number 6—June 2014

Volume 20, Number 6—June 2014


Buruli Ulcer Disease in Republic of the Congo

To the Editor: Buruli ulcer, which is caused by theMycobacterium ulcerans bacterium, is a severe disabling necrotic disease of the skin, occurring mainly in swampy rural areas of western and central Africa. This tropical disease is neglected, despite being the third most common mycobacterial disease of humans, after tuberculosis and leprosy. The disease has become substantially more frequent over the past decade, particularly around the Gulf of Guinea, and has been detected or suspected in at least 31 countries (1). Clinical diagnosis of Buruli ulcer disease should be confirmed by PCR, as recommended by the World Health Organization (WHO); and case-patients should be treated with rifampin/streptomycin daily for 8 weeks (therapy available since 2004), combined, if necessary, with surgery.
Thumbnail of Buruli ulcer–endemic areas in the Republic of the Congo (RC) and neighboring countries. A) Buruli ulcer cases have been reported in all countries neighboring RC. CAR, Central African Republic; DR Congo, Democratic Republic of the Congo. B) RC (representing the white area in panel A). The numbers indicate the 7 departments or communes (of 12 total) where PCR-positive cases of Buruli ulcer disease were diagnosed. 1, Kouilou Department; 2 Pointe Noire Commune; 3, Niari Department; 4, B
Figure. Buruli ulcer–endemic areas in the Republic of the Congo (RC) and neighboring countriesA) Buruli ulcer cases have been reported in all countries neighboring RCCAR, Central African Republic; DR Congo, Democratic Republic...
Although confirmed cases of Buruli ulcer disease have been reported in all countries neighboring the Republic of the Congo (hereafter called Congo) (24), only 1 report of a confirmed case in Congo has been published (5) (Figure, panel A). During 2007–2012, a total of 573 clinical cases of Buruli ulcer disease were reported to WHO by the National Leprosy, Buruli Ulcer and Yaws Control Program in Congo. We report 108 cases (19% of all cases reported) that were confirmed, in accordance with WHO recommendations, by quantitative PCR, the most sensitive and specific testing method available (6).
The National Leprosy, Buruli Ulcer, and Yaws Control Program, with the support of the Raoul Follereau Foundation (Paris, France), performed passive and active surveillance of Buruli ulcer in Congo during 2007–2012. Fine-needle aspirate or swab samples were obtained from patients with suspected Buruli ulcer and sent to Angers University Hospital (Angers, France) for confirmation by quantitative PCR as described (6,7). Of the 283 samples analyzed, 114 (40%) from 108 different patients were PCR positive. Of the 114 PCR-positive samples, 20 (18%) were fine-needle aspirate samples and 94 (82%) were swab samples (at least 2 swabs/lesion). The 108 case-patients included 60 (56%) female and 48 (44%) male patients; 56% of the case-patients were <15 years of age. The most common clinical form of the disease (86% of cases) was the ulcerative stage with edema or plaque. All confirmed Buruli ulcer case-patients were treated in accordance with WHO recommendations (8): antibiotic treatment (rifampin/streptomycin) plus surgery if necessary. All patients with nonconfirmed cases were treated according to the alternative diagnosis reached by the clinician.
Our findings show that Buruli ulcer disease affects persons in several of Congo’s administrative divisions (Figure, panel B); of the 108 patients, 77 (71%) were from Kouilou Department (Figure,panel C). The village of residence was recorded for 55of these 77 patients, 46 (84%) of whom lived in 9 villages along the Kouilou River, encompassing an area of ≈50 km × 20 km: Madingo-Kayes, Kanga, Loukouala, Mfilou, Koubotchi, Mboukoumassi, Tchisseka, Magne, and Loaka villages. This disease-endemic area includes 2 lakes, Dinga and Nanga, both of which are fed by the Kouilou River. The remaining 31 (29%) confirmed patients (i.e., those not living in Kouilou Department) lived in Niari Department (9%), Bouenza Department (6.5%), Pool Department (3%), or Cuvette Department (5.5%) or in Pointe Noire Commune (2%) or Brazzaville Commune (3%) (Figure, panel B).
The distribution of Buruli ulcer cases in Congo is unusual. The Kouilou River region was most affected, but several other areas, all in southern Congo, have confirmed Buruli ulcer patients. Cuvette Department is the 1 exception; although it is in northeastern Congo, this department did have a cluster of cases. The cases in Cuvette were identified (and the infections were diagnosed and treated) during active research into Buruli ulcer during 2009–2010. (Note that there has been no survey in this region since 2010.)
Buruli ulcer is also endemic in some areas of the countries neighboring Congo. In the Democratic Republic of the Congo, the disease is highly endemic in the Bas Congo region, which shares a border with departments in southern Congo where the disease is endemic (9). By contrast, the small cluster of cases diagnosed in Cuvette Department in northeastern Congo seems to be isolated from other areas where the disease is known to be endemic.
M. ulcerans is known to be associated with wetlands, and the Kouilou River environment is certainly suitable for its spread (10). Identification of this zone as a high-risk area for Buruli ulcer disease will help the Ministry of Health improve early detection, biological confirmation, and treatment programs. In the other regions, active and continuous surveillance is necessary to establish a detailed map of the villages and areas where Buruli ulcer disease is endemic; such information would enable the implementation of targeted control activities. However, active surveillance in Congo has substantially declined since 2011. Our findings support the reactivation of such surveillance campaigns to ensure the early identification and confirmation of Buruli ulcer cases and to improve patient management.
Estelle MarionComments to Author , Damas Obvala, Jeremie Babonneau, Marie Kempf, Kingsley B. Asiedu, and Laurent Marsollier
Author affiliations: Fondation Raoul Follereau, Pobè, Bénin (E. Marion)Centre Hospitalier Universitaire d’Angers, Angers, France (E. Marion, J. Babonneau, M. Kempf, L. Marsollier)INSERM, Angers (E. Marion, J. Babonneau, L. Marsollier)Ministère de la Santé, Brazzaville République du Congo (D. Obvala)World Health Organization, Geneva, Switzerland (K.B. Asiedu)


This work was supported by the Fondation Raoul Follereau, the Institut National de la Santé et de la Recherche Médicale (INSERM, Programme INSERM Avenir); Agence Nationale de la Recherche (ANR 11 CEPL 007 [EXTRA-MU]), and Agence Nationale de Recherche sur le SIDA et les Hépatites (Programme INSERM Avenir).


  1. Walsh DSPortaels FMeyers WMBuruli ulcer: advances in understandingMycobacterium ulcerans infection. Dermatol Clin2011;29:18DOIExternal Web Site IconPubMedExternal Web Site Icon
  2. Kibadi KPanda MTamfum JJFraga AGLongatto Filho AAnyo GNew foci of Buruli ulcer, Angola and Democratic Republic of Congo. Emerg Infect Dis2008;14:17902DOIExternal Web Site IconPubMedExternal Web Site Icon
  3. Minime-Lingoupou FBeyam NZandanga GManirakiza AN'Domackrah ANjuimo S,Buruli ulcer, Central African Republic. Emerg Infect Dis2010;16:7468DOIExternal Web Site IconPubMedExternal Web Site Icon
  4. Ngoa UAAdzoda GKLouis BMAdegnika AALell BBuruli ulcer in Gabon, 2001–2010.Emerg Infect Dis2012;18:12067DOIExternal Web Site IconPubMedExternal Web Site Icon
  5. Kibadi KStragier PMuyembe-Tamfum JJPedrosa JPortaels FFollow-up of the first case of Mycobacterium ulcerans infection documented by PCR, genotyping and culture in the Republic of Congo-Brazzaville [in French]Med Trop (Mars)2008;68:13743.PubMedExternal Web Site Icon
  6. Cassisa VChauty AMarion EArdant MFEyangoh SCottin JUse of fine-needle aspiration for diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol.2010;48:22634DOIExternal Web Site IconPubMedExternal Web Site Icon
  7. Marion EEyangoh SYeramian EDoannio JLandier JAubry JSeasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLoS Negl Trop Dis2010;4:e731DOIExternal Web Site IconPubMedExternal Web Site Icon
  8. World Health Organisation. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. 2012 [cited 2013 Oct 10]. Adobe PDF fileExternal Web Site Icon
  9. Phanzu DMSuykerbuyk PImposo DBLukanu PNMinuku JBLehman LFEffect of a control project on clinical profiles and outcomes in Buruli ulcer: a before/after study in Bas-Congo, Democratic Republic of Congo. PLoS Negl Trop Dis2011;5:e1402DOIExternal Web Site IconPubMedExternal Web Site Icon
  10. Johnson PDStinear TSmall PLPluschke GMerritt RWPortaels FBuruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med2005;2:e108.DOIExternal Web Site IconPubMedExternal Web Site Icon


Suggested citation for this article: Marion E, Obvala D, Babonneau J, Kempf M, Asiedu KB, Marsollier L. Buruli ulcer in Republic of the Congo [letter]. Emerg Infect Dis. 2014 June [date cited]. Web Site Icon
DOI: 10.3201/eid2006.131498

No hay comentarios:

Publicar un comentario